| Lifestyle Hearing Corporation Usa Inc | |
|
11400 N Jog Rd, Palm Beach Gardens, FL 33418-1756 | |
| (561) 678-3394 | |
| (561) 453-3235 |
| Full Name | Lifestyle Hearing Corporation Usa Inc |
|---|---|
| Type | Facility |
| Speciality | Audiologist-hearing Aid Fitter |
| Location | 11400 N Jog Rd, Palm Beach Gardens, Florida |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316338346 | NPI | - | NPPES |
| Provider Name | Louis A Looper |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1194049379 PECOS PAC ID: 3779747696 Enrollment ID: I20120605000668 |
News Archive
Researchers have examined the potential benefits of melatonin, a hormone made by a small gland in the brain, for treating blood cancers such as leukemia and lymphoma.
A recent study by pediatricians from the Cohen Children's Medical Center of New York examined infants 0-3 years old that used touch-screen devices to determine if their use was of any educational benefit to infants and toddlers.
Oxford VR, a spinout company from the University of Oxford, has raised £3.2m with investors including Oxford Sciences Innovation, University of Oxford, Force Over Mass, RT Capital and GT Healthcare Capital Partners.
Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
› Verified 2 days ago
| Provider Name | Linda Vassallo |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1538448881 PECOS PAC ID: 0648404004 Enrollment ID: I20200826003635 |
News Archive
Researchers have examined the potential benefits of melatonin, a hormone made by a small gland in the brain, for treating blood cancers such as leukemia and lymphoma.
A recent study by pediatricians from the Cohen Children's Medical Center of New York examined infants 0-3 years old that used touch-screen devices to determine if their use was of any educational benefit to infants and toddlers.
Oxford VR, a spinout company from the University of Oxford, has raised £3.2m with investors including Oxford Sciences Innovation, University of Oxford, Force Over Mass, RT Capital and GT Healthcare Capital Partners.
Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
› Verified 2 days ago
| Provider Name | Jessica Hiers |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1275130163 PECOS PAC ID: 3577979822 Enrollment ID: I20210311000539 |
News Archive
Researchers have examined the potential benefits of melatonin, a hormone made by a small gland in the brain, for treating blood cancers such as leukemia and lymphoma.
A recent study by pediatricians from the Cohen Children's Medical Center of New York examined infants 0-3 years old that used touch-screen devices to determine if their use was of any educational benefit to infants and toddlers.
Oxford VR, a spinout company from the University of Oxford, has raised £3.2m with investors including Oxford Sciences Innovation, University of Oxford, Force Over Mass, RT Capital and GT Healthcare Capital Partners.
Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
› Verified 2 days ago
| Provider Name | Chenchen Zhang |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1366052680 PECOS PAC ID: 2668863705 Enrollment ID: I20211227000963 |
News Archive
Researchers have examined the potential benefits of melatonin, a hormone made by a small gland in the brain, for treating blood cancers such as leukemia and lymphoma.
A recent study by pediatricians from the Cohen Children's Medical Center of New York examined infants 0-3 years old that used touch-screen devices to determine if their use was of any educational benefit to infants and toddlers.
Oxford VR, a spinout company from the University of Oxford, has raised £3.2m with investors including Oxford Sciences Innovation, University of Oxford, Force Over Mass, RT Capital and GT Healthcare Capital Partners.
Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lifestyle Hearing Corporation Usa Inc 11400 N Jog Rd, Palm Beach Gardens, FL 33418-1756 Ph: (561) 678-3394 | Lifestyle Hearing Corporation Usa Inc 11400 N Jog Rd, Palm Beach Gardens, FL 33418-1756 Ph: (561) 678-3394 |
News Archive
Researchers have examined the potential benefits of melatonin, a hormone made by a small gland in the brain, for treating blood cancers such as leukemia and lymphoma.
A recent study by pediatricians from the Cohen Children's Medical Center of New York examined infants 0-3 years old that used touch-screen devices to determine if their use was of any educational benefit to infants and toddlers.
Oxford VR, a spinout company from the University of Oxford, has raised £3.2m with investors including Oxford Sciences Innovation, University of Oxford, Force Over Mass, RT Capital and GT Healthcare Capital Partners.
Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
› Verified 2 days ago